Halozyme Therapeutics | HALO - Selling And Administration Expenses


Halozyme Therapeutics reported $37.53M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Agios Pharmaceuticals USD 41.27M 4.6M Sep/2025
Alnylam Pharmaceuticals USD 262.59M 60.72M Sep/2025
Amarin USD 17.94M 17.86M Sep/2025
Amgen USD 1.7B 9M Sep/2025
Baxter International USD 708M 10M Sep/2025
Cytokinetics USD 158.75M 93.03M Sep/2025
DBV Technologies USD 3.63M 3.18M Sep/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
Halozyme Therapeutics USD 37.53M 4.53M Sep/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
MannKind USD 29.09M 2.53M Sep/2025
Pfizer USD 3.19B 209M Sep/2025
United Therapeutics USD 152M 60.5M Sep/2025